Collaboration Overview - Lunit has announced a collaboration with Daiichi Sankyo to enhance biomarker discovery and optimize translational research using Lunit SCOPE digital pathology products across two oncology programs [1][2][3] Technology and Applications - Daiichi Sankyo will utilize Lunit SCOPE solutions, including SCOPE uIHC for quantitative IHC analysis and SCOPE IO for immune phenotyping and spatial analysis, to identify novel biomarkers and improve clinical trial support [2][3] - Lunit SCOPE aims to extract insights from pathology slides, quantifying tumor microenvironments and predicting molecular profiles to inform trial design [3] Research and Development Impact - The collaboration will involve exploratory research projects across multiple cancer types, potentially influencing future trial designs, biomarker strategies, and clinical development plans [3] Company Background - Lunit, founded in 2013, is a leader in AI for cancer diagnostics, offering solutions that enhance early detection and treatment decisions across the cancer care continuum [4][5] - The company’s Lunit SCOPE platform is utilized in research partnerships for biomarker research and companion diagnostic development [5][6] Global Reach - Lunit's solutions are trusted by over 10,000 sites in more than 65 countries, combining medical expertise with evolving datasets to impact patients, clinicians, and researchers [6]

Core Insights - Lunit has announced a collaboration with Microsoft to enhance the delivery of AI-powered healthcare solutions, particularly in cancer diagnostics and therapeutics [1][2] - The partnership aims to develop integrated solutions that improve clinical workflows and diagnostic consistency in healthcare settings [3][4] Collaboration Highlights - Co-Development of AI Model Customization Service: The collaboration will focus on creating a service that fine-tunes AI models using site-specific clinical data, addressing performance variability across different clinical environments [5] - Leveraging Microsoft's AI Platform: Lunit will utilize Microsoft's AI frameworks to create end-to-end workflow automation tools, enhancing clinical decision-making and operational efficiency [6] Strategic Vision - The collaboration aligns with Lunit's long-term vision to provide scalable and accessible AI solutions integrated into clinical practice, particularly targeting the U.S. market through Microsoft Azure's infrastructure [4][7] - Both companies emphasize the importance of creating an ecosystem that supports the development of intelligent, integrated solutions for radiology and other healthcare areas [7] Company Background - Lunit, founded in 2013, is a leader in AI for cancer diagnostics, with its FDA-cleared Lunit INSIGHT suite used in over 6,500 medical institutions across more than 65 countries [8] - The company is committed to advancing cancer care through AI, with clinical studies published in prestigious journals and presented at major medical conferences [8]